Navigation Links
Overcoming inhibitors of cell death improves cancer therapy efficacy
Date:8/1/2008

Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely poor prognosis. Although pre-clinical studies indicated therapeutics inhibiting a group of proteins known as receptor tyrosine kinases (RTKs) would likely be beneficial to individuals with GBM, these RTK inhibitors have met with limited clinical success only a small proportion of patients respond to such treatment and most subsequently relapse after only a short time. New data, generated by Andrew Kung and colleagues, at the Dana-Farber Cancer Institute, Boston, have now provided insight into the mechanism by which GBM cells become resistant to RTK inhibitors and have suggested a way to improve the efficacy of RTK inhibitors in this clinical setting.

In the study, human GBM cells exposed in vitro to an inhibitor of the RTK PDGFR activated a cellular pathway that usually induces cells to undergo a form of cell death known as apoptosis, but the final steps of the pathway were not completed, meaning that the cells did not die. Further analysis revealed that the final steps of this pathway were blocked by a group of proteins known as IAPs. Consistent with this, if the PDGFR inhibitor was combined with an IAP inhibitor the GBM cells underwent apoptosis. Further, this drug combination showed enhanced efficacy at inhibiting tumor growth in an orthotopic mouse model of GBM. The authors therefore suggest that combining drugs targeting IAPs with RTK inhibitors might prove beneficial to individuals with GBM.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Overcoming Im in Control Syndrome and Providing Help When Patients Least Expect It Can Benefit Children and Teens With Asthma
2. VH1 Teams Up with Dr. Drew for Celebrity Rehab With Dr. Drew, a Series Depicting the Process of Overcoming Addiction
3. Cell skeleton may hold key to overcoming drug resistance in cancer
4. Myostatin inhibitors may improve recovery of wartime limb injuries
5. Team discovers new inhibitors of estrogen-dependent breast cancer cells
6. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
7. Gastric juice for diagnosis of H. pylori infection in patients on proton pump inhibitors
8. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
9. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
10. Silencing small but mighty cancer inhibitors
11. Sleep Apnea Boosts Death Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for ... today the election of Yie-Hsin Hung to the Board of Directors. , “The ... of Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Sagora Senior Living, one of ... Kingwood Assisted Living and Memory Care located at 24025 Kingwood Place Drive, Kingwood, ... living apartments, 43 memory care apartments and 23 extended care apartments. Modern floor ...
(Date:9/20/2017)... ... 2017 , ... Collins Concrete Coatings announced that they offer ... safety and cleanliness. This unique flooring system uses silver ion technology to resist ... for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ions attack ...
(Date:9/20/2017)... ... 20, 2017 , ... Mirror Mirror Beauty Boutique is excited ... This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include ... Beauty Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title ...
(Date:9/20/2017)... ... September 20, 2017 , ... Each ... for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research ... is also when Athletic Trainers are acknowledged by their peers with accolades and ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... Sept. 5, 2017 Sapheneia and Scannerside received ... Scannerside DoseCheck is a third-party Vendor neutral CT product ... and allows compliance with current MITA standards. ... 29 DoseCheck solution is specifically designed to provide CT ... potential radiation doses over a predefined threshold. Scannerside Dose ...
(Date:9/5/2017)... WAYNE, N.J. , Sept. 5, 2017 /PRNewswire/ ... technology, has created a vibrant charitable donation program ... funds and support congenital heart defect research by ... healthcare providers and the general public are encouraged ... and submit the completed artwork to the ...
Breaking Medicine Technology: